Welcome to our dedicated page for MANGOCEUTICALS SEC filings (Ticker: MGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mangoceuticals, Inc. filings document a Nasdaq Capital Market-listed wellness telemedicine company, its MangoRx and PeachesRx brands, and securities issued to finance corporate operations. The company’s regulatory record includes Form 8-K reports on product communications, MGX-0024 data, branded GLP-1 program disclosures, litigation-related press releases, Nasdaq listing-rule notices and equity-compensation actions.
Registration statements and amendments describe the company’s securities offerings, capital structure, financial statements and risk disclosures. Other filings address common stock, warrants and pre-funded warrants, board and committee approvals, executive compensation arrangements, material events and forward-looking statement qualifications tied to Mangoceuticals’ telehealth platform, wellness products and public-company obligations.
Filing highlight: Mangoceuticals, Inc. (CIK 0001938046; symbol MGRX) has received a formal Notice of Effectiveness from the U.S. Securities and Exchange Commission.
The SEC declared the company’s Form S-1 registration statement (File No. 333-287689) effective at 5:00 p.m. on June 18, 2025. This notice confirms that the registration statement has completed the Commission’s review and is now operative.
No further details—such as the size, terms, or purpose of the registered securities—were disclosed in the notice.